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Introduction 
 
Positron emission tomography (PET) is a power-
ful non-invasive imaging technique which allows 
quantification of biochemical and pharmacody-
namic processes in healthy and diseased 
states. In drug discovery and development, PET 
offers opportunities to investigate drug-target 
interactions in vivo and to monitor the effects of 
a drug candidate on the progression of a dis-
ease [1, 2]. The design of PET probes which 
selectively target a particular receptor, enzyme 
or transporter is a major challenge in further 
advancement of PET technique. Besides ana-
logues of endogenous substrates such as [18F]-
fluorodeoxyglucose ([18F]-FDG) or [11C]- or [18F]-
labelled amino acids [3, 4], small synthetic or-
ganic molecules are emerging as promising 
scaffolds for the development of highly selective 
PET probes.  
 
Metabotropic glutamate receptor subtype 5 
(mGluR5) is a seven transmembrane domain, G-
protein coupled receptor, belonging to group I of 
the metabotropic glutamate receptors and it is 
mainly located postsynaptically [5-7]. mGluR5 is 
involved in long-term potentiation processes [8] 
and plays a role in several disorders  of central 
nervous system (CNS) such as schizophrenia, 
depression, anxiety, Alzheimer and Parkinson’s 
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disease [9-14]. It is considered an important 
future drug target and much attention has been 
given to the development of an optimal PET 
tracer for imaging of mGluR5 [15].  
 
It was not until the development of synthetic 
mGluR5 antagonist 2-methyl-6-( phenylethynyl) 
pyridine (MPEP) [16, 17], which unlike amino 
acid derived ligands acts via the non-
competitive mechanism and not at the con-
served glutamate binding site, that significant 
research efforts were made. This led to the de-
velopment of (E)-3-((6-methylpyridin-2-yl)ethynyl)
cyclohex-2-enone-O-11C-methyl oxime ([11C]-
ABP688, Figure 1) by the Ametamey group [18, 
19] which is to date the most successful clini-
cally applied mGluR5 PET tracer. Despite its 
excellent properties as a PET imaging agent in 
human subjects [19], [11C]-ABP688 does have 
one limitation and this is due to the short physi-
cal half-life (20 min) of carbon-11 which limits 
its application to facilities with an on-site cyclo-
tron. This has provoked further research efforts 
towards the development of 18F-labelled PET 
tracers, which have a longer physical half-life 
(109.8 min). To date, the two most successful 
mGluR5 18F-labelled PET tracers are 3-fluoro-5-
(2-(2-[18F](fluoromethyl)-thiazol-4-yl)-ethynyl)
benzonitrile ([18F]-SP203) developed by the Pike 
group [20-22] and 3-[18F]fluoro-5-(2-
pyridinylethynyl)benzonitrile ([18F]-FPEB) from 
the Hamill group [23-25] (Figure 1). However, 
the first undergoes significant defluorination in 
rodents and monkeys and to a lesser extent in 
humans and the latter is typically obtained in 
low radiochemical yields. 
 
Our group aimed to develop a fluorine-18 ana-
logue of [11C]-ABP688 with the same excellent 
imaging properties as [11C]-ABP688, but with 
added advantage of a longer physical half-life. 
Several derivatives were prepared [26, 27] and 
evaluated which finally led to the development 
of (E)-3-(pyridin-2-ylethynyl)cyclohex-2-enone O-
(2-(2-18F-fluoroethoxy)ethyl) oxime ([18F]-
FDEGPECO) [28, 29], which maintained the 
same [11C]-ABP688 scaffold, but the oxime 
functionality was additionally adorned with a six-
atom long lipophilic chain (as oppose to a 
methyl in [11C]-ABP688) [1, 2, 30, 31]. The in 
vivo evaluation of [18F]-FDEGPECO allowed visu-
alization of mGluR5 in the rat brain, albeit with 
a lower relative accumulation and shorter resi-
dence time in mGluR5-rich brain regions than 
observed for [11C]-ABP688, which prompted us 
to re-evaluate the structure of [18F]-FDEGPECO. 
The lipophilicity of [18F]-FDEGPECO is signifi-
cantly lower than that of [11C]-ABP688 [18], and 
we chose to   pursue an [18F]-FDEGPECO ana-
logue (E)-3-(Pyridin-2-ylethynyl)cyclohex-2-enone 
O-(2-(3-18F-fluoropropoxy)ethyl) oxime ([18F]-
PSS223, Figure 1) in which the side chain func-
tionality is extended by one methylene group 
with the aim to increase the lipophilicity towards 
that of [11C]-ABP688 [28, 32]. 
 
In this manuscript we report on the synthesis, 
radiolabelling, in vitro and in vivo evaluation of 
this novel compound ([18F]-PSS223).  The PET 
images of ([18F]-PSS223 are also compared with 
Figure 1. Structures of MPEP and selected PET tracers for imaging of mGluR5. 
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those obtained with [11C]-ABP688 and [18F]-
FDEGPECO. 
 
Materials and methods 
 
General 
 
All reactions requiring anhydrous conditions 
were conducted in flame-dried glass apparatus 
under an atmosphere of inert gas. All chemicals 
and anhydrous solvents were purchased from 
Aldrich or ABCR and used as received unless 
otherwise noted. [3H]-ABP688 (2.405 GBq/
mmol, 37 MBq/mL solution in EtOH) was ob-
tained from AstraZeneca. 3-Ethynylcyclohex-2-
enone, (E)-3-ethynylcyclohex-2-enone oxime  
and (E)-3-(pyridin-2-ylethynyl)cyclohex-2-enone 
oxime (5) were prepared as previously reported 
and the characterization data is in complete 
agreement with those previously reported [28, 
33]. To obtain (E)-3-((6-Methylpyridin-2-yl)
ethynyl)cyclohex-2-enone O-[11C]-methyl oxime 
([11C]-ABP688) radiolabelling was performed 
using module system as previously described 
[18, 34].  
 
Preparative chromatographic separations were 
performed on Aldrich Science silica gel 60 (35-
75 μm) and reactions followed by TLC analysis 
using Sigma-Aldrich silica gel 60 plates (2-25 
μm) with fluorescent indicator (254 nm) and 
visualized with UV or potassium permanganate.  
 
Infrared spectra were recorded on a JASCO FT/
IR 6200 (OmniLab) spectrometer using a chloro-
form solution of compound. 1H and 13C NMR 
spectra were recorded in Fourier transform 
mode at the field strength specified on Bruker 
Avance FT-NMR spectrometers. Spectra were 
obtained from the specified deuterated solvents 
in 5 mm diameter tubes. Chemical shift in ppm 
is quoted relative to residual solvent signals 
calibrated as follows: CDCl3 δH (CHCl3) = 7.26 
ppm, δC = 77.2 ppm; (CD3)2SO δH (CD3SOCHD2) 
= 2.50 ppm, δC = 39.5 ppm. Multiplicities in the 
1H NMR spectra are described as: s = singlet, d 
= doublet, t = triplet, q = quartet, quint. = quin-
tet, m = multiplet, b = broad; coupling constants 
are reported in Hz. Numbers in parentheses 
following carbon atom chemical shifts refer to 
the number of attached hydrogen atoms as re-
vealed by the DEPT spectral editing technique. 
Electrospray (ES) mass spectra (LRMS) were 
obtained with a Micromass Quattro micro API LC 
electrospray ionization and electrospray (ES) 
mass spectra (HRMS) were obtained with a 
Bruker FTMS 4.7 T BioAPEXII spectrometer. 
Electron-impact (EI) and chemical ionisation (CI) 
mass spectra (LRMS and HRMS) were obtained 
with a Waters Micromass AutoSpec Ultima 
MassLynx 4.0 spectrometer. Ion mass/charge 
(m/z) ratios are reported as values in atomic 
mass units. 
 
Semi-preparative purification of radiolabelled 
material was performed on a Merck-Hitachi 
L6200A system equipped with Knauer variable 
wavelength detector and an Eberline radiation 
detector using a reverse phase column (C18 
Phenomenex Gemini, 5 mm, 250x10 mm) and 
eluting with gradient: 0-5 min 5% aq. MeCN, 5-
15 min 5-50% aq. MeCN, 15-30 min 50% aq. 
MeCN, 30-50 min, 50-90% aq. MeCN, 50-65 
min, 65% MeCN at flow rate 5 mL/min.  Analyti-
cal HPLC samples were analyzed by Agilent 
HPLC 1100 system equipped with UV multi-
wavelength detector and Raytest Gabi star ra-
diation detector using reverse phase column 
(ACE 111-0546, C18, 3 mm, 50x4.6 mm) and 
eluting with 45% aq. MeCN at flow rate 1 mL/
min. Samples for PBS, plasma and microsome 
stability were analyzed by Waters ultra-
performance liquid chromatography (UPLCTM) 
system equipped with Berthold coincidence de-
tector (FlowStar LB513) using UPLC column 
(Waters Acquity BEH C18, 1.7 mm, 50x2.1 mm) 
and eluting with gradient 0-70% aq. MeCN over 
5 min at flow 0.7 mL/min or for microsome as-
say with 30% aq. MeCN over 5 min at flow 0.7 
mL/min.  
 
Bovine serum albumin was purchased from 
Acros Organics. Pooled human liver micro-
somes, pooled liver microsomes from male 
Spargue Dawley rats (20 mg protein per mL) 
and NADPH regenerating system (A: 31 mM 
NADP+, 66 mM glucose-6-phosphate, 66 mM 
MgCl2; B: 40 U/mL glucose-6-phosphate dehy-
drogenase) were obtained from BD Biosciences.  
 
Male Wistar rats were obtained from Charles 
River (Sulzfeld, Germany). Animal care and all 
experimental procedures were approved by the 
Cantonal Veterinary Office in Zurich, Switzer-
land. The animals were allowed free access to 
food and water. 
 
Radiosynthesis 
 
(E)-3-(Pyridin-2-ylethynyl)cyclohex-2-enone O-(2-
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(3-18F-fluoropropoxy)ethyl) oxime ([18F]-
PSS223): No-carrier-added [18F]-fluoride was 
produced via nuclear 18O(p, n)18F reaction from 
enriched 18O-water using IBA cyclone 18/9 cy-
clotron and it was immediately trapped on a 
QMA cartridge (preconditioned with 0.5 M aq. 
K2CO3 (1x5 mL), then H2O (1x5 mL) and dried in 
air). The trapped [18F]-fluoride was eluted from 
the cartridge with 0.25% wt Kryptofix-222® solu-
tion (1 mL) in basic (0.05% wt K2CO3) aq MeCN 
(75% vv) into a tightly closed reaction vial. The 
solvents were evaporated in vacuo (130 mbar) 
with gentle stream of N2 gas at 110 °C over 5 
min. To the resulting solid residue anhydrous 
MeCN (1 mL) was then added and the mixture 
was azeotropically dried in vacuo (130 mbar) 
with gentle stream of N2 at 110 °C. To the dried 
Kryptofix-222®/[18F–] complex a solution of     
(E)-3-(2-(((3-(pyridin-2-ylethynyl)cyclohex-2-en-1-
ylidene)amino)oxy)ethoxy)propyl methanesul-
fonate (2.44 mg, 6.22 µmol) in anhydrous N,N`-
dimethylformamide (0.3 mL) was added and the 
dark brown mixture was heated at 90 °C for 10 
min. The crude mixture was diluted with 50% vv 
aq. MeCN (2 mL) and purified via semi-
preparative HPLC. The desired product was col-
lected (retention time: 31.9 min) and immedi-
ately diluted with H2O (10 mL). The aqueous 
solution was passed through a C18 cartridge 
(preconditioned with EtOH (1x5 mL), then H2O 
(1x5 mL) and dried in air) and the cartridge was 
washed with H2O (2x1 mL) and the product was 
eluted from the C18 cartridge with EtOH (1x0.3 
mL) in a sterile vial containing 50% aq. PEG200 
(5 mL) to afford the radiolabelled title com-
pound in 20% decay corrected yield. Typically 
starting from ca. 30 GBq of activity, 5-6 GBq of 
product was obtained. The radiochemical purity 
was >97% and specific activity in the range of 
100-320 GBq/mmol.  
 
Determination of logD 
 
For purposes of logD determination a further 
product elution from the C18 cartridge was car-
ried out using EtOH (0.3 mL) and the solvent 
was evaporated in vacuo (100 mbar) at 90 °C 
for 5 min.  
 
The determination of logD value was performed 
using the shake-flask method as previously re-
ported [28, 35]. [18F]-PSS223 (453 MBq) was 
partitioned between phosphate buffer (pH 7.4) 
saturated with 1-octanol (2 mL) and 1-octanol 
saturated with phosphate (pH 7.4) buffer (2 
mL). The octanol (top) phase (0.5 mL) was 
washed with phosphate (pH 7.4) buffer satu-
rated with 1-octanol (2x0.5 mL). The purity of 
the material (14 MBq) was confirmed by HPLC 
analysis. Finally washed octanol phase (0.1 mL) 
was diluted with phosphate (pH 7.4) buffer satu-
rated with 1-octanol (0.1 mL) and the two 
phases were shaken and radioactivity in each 
phase was measured in a -counter. 
 
Pharmacology 
 
Competition Binding Assay 
 
Brain membranes were prepared from Sprague 
Dawley rat brains as described previously [28]. 
Frozen membranes were thawed on ice and 
pelleted at 45000xg at 4 °C for 5 min. The 
membranes were washed twice with HEPES 
buffer (30 mM HEPES, 110 mM NaCl, 5 mM 
KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, pH 8 at 4°C) 
and resuspended in HEPES buffer at a protein 
concentration of 1.3 mg/mL. The binding assay 
was performed as previously described [28]. In 
brief, brain membranes (0.1 mg protein) were 
incubated in triplicates at ambient temperature 
with 2 nM [3H]ABP688 and PSS223 at concen-
trations between 10 pM and 100 M in a total 
volume of 0.2 ml HEPES. PSS223 was diluted 
from a 1 mM ethanolic (50%) solution. The cor-
responding EtOH concentrations did not affect 
[3H]ABP688 binding (data not shown). Unspe-
cific binding of [3H]ABP688 was estimated with 
100 M MMPEP. After 45 min, the samples 
were filtrated and the filters containing the 
membranes with bound [3H]ABP688 were 
measured in a β-counter (Beckman LS6500). 
Bound [3H]ABP688 (B, pmol per mg protein) 
was fitted with Excel solver to Equation 1 to esti-
mate IC50. 
 
B = Bmin + ((Bmax – Bmin)/(1 + (C/IC50)))    Eq. 1 
 
where C is the total PSS223 concentration, Bmax 
is the maximal B, i.e., the plateau in the B/C 
plot at low log C and Bmin is the minimal B, i.e., 
the plateau at high log C. The inhibition con-
stant Ki of PSS223 was estimated from IC50 and 
Kd of ABP688 (1.7±0.2 nM) [18] with the Cheng
-Prusoff equation.   
 
Saturation Binding Assay 
 
Brain membranes were incubated with [18F]-
PSS223 at concentrations between 0.25 and 
Development of novel mGluR5 PET tracer  
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100 nM as described above. Unspecific binding 
was determined with 100 M MMPEP. After 
filtration, bound [18F]-PSS223 was quantified in 
a g-counter (PerkinElmer, Wizard) and Kd was 
estimated according to Equation 2, 
 
Bspec = (Bmax,spec x 1/Kd x Cu)/(1 + 1/Kd x Cu)     Eq. 2 
 
where Bspec is the difference between B and the 
unspecific binding (at 100 M MMPEP) and Cu 
is the unbound concentration, i.e. the difference 
between the total and the bound concentra-
tions. Bmax,spec is the maximal Bspec at receptor 
saturation. Three independent experiments 
were performed with [18F]-PSS223 obtained 
from three independent radiolabelling produc-
tions.  
 
In vitro autoradiography 
 
Frozen horizontal brain slices (20 mm) from a 
male Wistar rat (492 g) adsorbed to SuperFrost 
Plus slides were thawed at ambient tempera-
ture and preincubated on ice for 10 min in 
HEPES buffer (see above) containing 0.1% bo-
vine serum albumin (BSA). Excess solution was 
carefully removed and slides were incubated 
with 1 nM [18F]-PSS223 alone or together with 
100 nM ABP688 or 100 nM JNJ16259685 in 
HEPES buffer for 45 min at ambient tempera-
ture. After incubation, the solutions were de-
canted and the slides washed on ice in HEPES 
buffer containing 0.1% BSA, and twice in HEPES 
buffer (3 minutes each) and finally dipped in 
H2O. Dried slides were exposed to a phosphor 
imager plate for 30 min and the plate was 
scanned in a BAS5000 reader (Fuji).  
 
Stability in PBS and plasma 
 
[18F]-PSS223 (7-8 MBq) was incubated in phos-
phate buffer (4 mM KH2PO4/Na2HPO4, 155 mM 
NaCl, pH 7.4) or rat plasma at 37 °C for up to 2 
h. At different time points, samples were diluted 
and enzymatic reactions stopped with ice cold 
MeCN (140 mL). Plasma samples were centri-
fuged at 12000xg for 10 min. The samples were 
filtered and supernatants were analyzed by 
UPLC.   
 
Microsome stability assay 
 
[18F]-PSS223 (15 MBq) was preincubated for 5 
min at 37 °C with 50 mL NADPH regenerating 
system A, 10 mL NADPH regenerating system B, 
200 mL phosphate buffer (0.5 M, pH 7.4) and 
H2O in a total volume of 975 mL. Rat or human 
liver microsomes (25 mL) were added at a final 
protein concentration of 0.5 mg/mL at time 0. 
The mixture was incubated at 37 °C at 600 rpm 
and 100 mL aliquots were removed at the indi-
cated time points and immediately quenched 
with the same volume of ice-cold MeCN. Pro-
teins were precipitated at 12000xg (3 min) and 
the supernatants were filtered and analyzed by 
UPLC. NADPH regenerating system and micro-
somes were replaced by water, respectively in 
two control experiments. 
 
PET scans 
 
Rats were immobilized by anaesthesia with 2-
3% isoflurane in oxygen/air on a GE Vista ex-
plore PET/CT scanner with the head in the field 
of view. Body temperature was controlled with a 
rectal probe connected to a 37 °C air blower 
and respiratory frequency was monitored with a 
1025T Small Animal Monitoring and Gating Sys-
tem from SA Instruments (Sony Brook, NY, USA). 
At the start of data acquisition 15-30 MBq [18F]-
PSS223 or [11C]-ABP688 was injected into a tail 
vein and data were collected in list mode for 90 
and 60 min, respectively. After the PET scan, a 
CT was performed for anatomical orientation. 
PET data were reconstructed with 2D ordered 
subset expectation maximization (2D OSEM) 
and analyzed with PMOD 3.2 (PMOD, Zurich, 
Switzerland).   
 
Results 
 
Synthesis and radiolabelling 
 
The syntheses of the cold reference compound 
PSS223 and the desired radiolabelled analogue 
were accomplished via key intermediate 8 
which was envisioned to originate from oxime 5 
via SN2 reaction with bromoether 4. Oxime 5 
was prepared by a Sonogashira reaction [36] 
using commercially available 2-bromopyridine 
and (E)-3-ethynylcyclohex-2-enone oxime as 
previously reported [33] (Supporting data).  
 
Monoprotection of commercially available pro-
panediol with TBSCl, followed by esterification 
of the free hydroxyl group afforded ester 3 in 
40% yield. Ester 3 was then reduced to the cor-
responding ether with triethylsilane [37] in a 
reaction catalyzed by indium(III)-bromide (Figure 
2). 
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Bromoethers 4a and 4b were reacted with 
oxime 5 to afford alcohol 7 after deprotection of 
silyl ethers with TBAF in 48% yield. Finally, me-
sylation of 7 afforded the desired precursor 8 
which was used for the syntheses of PSS223 
and [18F]-PSS223 (Figure 2). In the presence of 
Kryptofix-222®, nucleophilic substitution of me-
sylate 8 with potassium fluoride gave reference 
compound PSS223 in 70% yield. Under analo-
gous conditions [18F]-PSS223 was obtained in 
20% radiochemical decay corrected yield. The 
identity of [18F]-PSS223 was confirmed by HPLC 
analysis via co-injection with cold PSS223.  
 
In vitro evaluation 
 
The experimentally determined logDpH7.4 of [18F]-
PSS223 was 1.89±0.05. The binding affinity of 
PSS223 was first estimated from a single com-
petition binding experiment with 2 nM [3H]-
ABP688 (Figure 3A). The estimated IC50 value 
was 14 nM and the respective Ki value 
amounted to 6 nM. The maximal displacement 
of [3H]-ABP688 by PSS223 was similar as ob-
served with 100 M MMPEP, i.e., about 96% of 
total binding. Next, we determined Kd of [18F]-
PSS223 in a saturation binding assay. Non-
linear curve fitting of three independent experi-
ments revealed a Kd of 3.34±2.05 nM and Bmax 
ranging from 2 to 6 pmol/mg. Linearization in 
the Scatchard plot confirmed a single binding 
site (Figure 3B). Non-specific binding was esti-
mated with an excess of MMPEP [38, 39].  
 
In vitro autoradiography with rat brain slices 
showed heterogeneous radioactivity distribution 
Figure 2. Syntheses of PSS223 and [18F]-PSS223 from key intermediate 8 via SN2 reaction. 
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after incubation with 1 nM [18F]-PSS223 (Figure 
4A). Highest radioactivity was observed in stria-
tum, hippocampus and cortex, regions known to 
express high levels of mGluR5 [40-42]. As ex-
pected from low mGluR5 expression in cerebel-
lum [5], binding to this brain region was negligi-
ble. Figure 4B shows the displacement of [18F]-
PSS223 with an excess of ABP688, confirming 
the specificity of [18F]-PSS223 for mGluR5. To 
demonstrate selectivity of [18F]-PSS223 for 
mGluR5 over mGluR1, the receptor with closest 
sequence similarity to mGluR5, brain slices 
were incubated with 1 nM [18F]-PSS223 and an 
excess of the mGluR1 antagonist JNJ16259685 
(Figure 4C). Binding competition was not ob-
served in this case, confirming the selectivity of 
[18F]-PSS223 for mGluR5.   
 
[18F]-PSS223 was stable over 120 minutes in 
phosphate buffer and rat plasma at 37 °C. 
However, incubation with rat liver microsomes 
and NADPH under aerobic conditions resulted in 
Figure 3. A. Displacement of [3H]-ABP688 by PSS223. [3H]-ABP688 (total 2 nM) binding (B) as a function of the 
PSS223 concentration. Symbols represent mean±SD of one experiment performed in triplicate. Non-linear fitting (red 
line) resulted in IC50 14 nM and corresponding Ki 6 nM; B. Scatchard plot analysis of the specific binding of [18F]-
PSS223 to rat brain membranes. Symbols, specific binding (total binding minus binding in the presence of 100 M 
MMPEP) of one representative experiment; red line, linear regression. 
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a significant decrease of [18F]-PSS223 and the 
appearance of a polar radiometabolite, co-
eluting with co-injected [18F]-fluoride. After one 
hour, about 90% of [18F]-PSS223 was metabo-
Figure 4. In vitro autoradiography with rat brain slices. A. Incubation with 1 nM [18F]-PSS223 showing heterogeneous 
distribution with highest expression in striatum, hippocampus and cortex; B. Brain slices incubated with 1 nM [18F]-
PSS223 and 100 nM ABP688; C. Brain slices incubated with 1 nM [18F]-PSS223 and 100 nM mGluR1 antagonist 
JNJ16259685. Blue, green, orange, red, dark red indicate radioactivity from low to high. Columns represent same 
experiment performed in duplicate.  
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lized under the chosen experimental conditions 
(Figure 5A). Incubation of [18F]-PSS223 with 
human liver microsomes under otherwise analo-
gous conditions resulted in 20% decrease of 
[18F]-PSS223 after one hour (Figure 5B) and the 
generation of two polar radiometabolites, the 
more polar one co-eluting with [18F]-fluoride. 
None of the polar compounds were detected in 
the absence of microsomes or NADPH.  
In vivo evaluation 
 
Dynamic PET scans were 
performed with two rats to 
determine whether [18F]-
PSS223 could be used to 
image brain regions express-
ing mGluR5. Figure 6A 
shows a transversal plane 
across the head region over 
time. In the early time 
frames, brain perfusion re-
sulted in high homogenous 
radioactivity in the brain. 
This was followed by a rapid 
washout from all brain re-
gions and radioactivity accu-
mulation in the skull and 
jaws. The time activity 
curves of mGluR5-rich brain 
regions and cerebellum 
show accumulation of [18F]-
PSS223 in striatum, hippo-
campus and cortex (Figure 
6B). However, the mean 
residence time was rela-
tively short and radioactivity 
approached cerebellum lev-
els already after about 20 
minutes. High accumulation 
of 18F-radioactivity in bone is 
demonstrated by the time 
activity curve of the jaws.  
 
Figure 7 shows a compari-
son of PET scans with [11C]-
ABP688, [18F]-FDEGPECO 
and [18F]-PSS223, all aver-
aged from 2 to 45 min after 
tracer injection. [18F]-
PSS223 data are from the 
same scan shown in Figures 
6A and B. The [18F]-
FDEGPECO image was re-
constructed from the data 
shown in our recent publica-
tion [29, 43]. Comparing the three tracers, [11C]-
ABP688 showed the highest relative radioactiv-
ity accumulation in mGluR5-rich brain regions 
such as hippocampus and striatum. [18F]-
FDEGPECO also allows visualization of mGluR5-
rich regions in the brain, however, at a higher 
background radioactivity. Our newest derivative, 
[18F]-PSS223 shows only weak accumulation in 
mGluR5-rich brain regions and significant accu-
Figure 5. A. Metabolism of [18F]-PSS223 by rat liver microsomes. Green 
symbols, [18F]-PSS223; blue symbols, polar 18F-radiometabolite; lines, 
fitted exponential functions; B. Metabolism of [18F]-PSS223 by human 
liver microsomes. Green symbols, [18F]-PSS223; blue and red symbols, 
polar 18F-radiometabolites. 
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Figure 6. A. PET dynamic scan of the head of a male Wistar rat injected with [18F]-PSS223. Transverse planes through 
the head summarized for the indicated time windows. White, CT; B. Time activity curves of [18F]-PSS223 uptake in a 
male Wistar rat in different brain regions showing increasing uptake in jaw due to rapid defluorination. 
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mulation of radioactivity in the skull and jaws as 
a result of rapid defluorination. 
 
Discussion 
 
Reference compound PSS223 was prepared in 
an overall satisfactory yield and all compounds 
en route were fully characterized (NMR, IR, MS). 
The synthesis of bromoether 4 proved to be 
more challenging than initially anticipated. After 
several unsuccessful attempts to obtain com-
pound 4 via direct functionalization with diha-
loethane, an alternative approach was em-
ployed and yielded the desired bromoether 4 in 
5% overall yield from three steps. During the 
reduction of the ester functionality in 3, the TBS 
silyl ether was partially substituted by the TES 
group (originating from the reagent triethylsi-
lane) to afford a mixture of TBS:TES silylethers 
in a ratio of 2:1 (4a:4b, Figure 2). For our pur-
poses, it was not necessary to separate the silyl 
ethers 4a and 4b since they were removed to 
afford free hydroxyl group in the following step.  
 
The radiosynthesis of [18F]-PSS223 was accom-
plished in a single step from mesylate precursor 
8 reproducibly in a good radiochemical yield. 
Pure radiotracer was obtained after HPLC semi-
preparative purification in a total radiosynthesis 
time of 90 min (from the end of bombardment). 
Experimentally determined logD value of [18F]-
PSS223 was 0.2 log units higher than that of 
[18F]-FDEGPECO (1.7±0.1) [28] and 0.5 log 
units lower than that of [11C]-ABP688 [18]. This 
was within the optimal lipophilicity range of high 
affinity ABP688 analogues, (i.e., ClogP value 
below 2.5 and logP between 0.9 and 2.5, range 
of values desired for fast blood-brain barrier 
passage) [32]. One may assume that for those 
ABP688 analogues logDpH7.4 corresponds to 
Figure 7. Rat brain PET images of [11C]-ABP688, [18F]-FDEGPECO and [18F]-PSS223. Planes (crosshairs) and maximal 
intensity projections (MIP) averaged from 2 to 45 min after tracer injection.  
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logP as both the pyridine and the oxime nitro-
gen atoms are non-protonated at pH 7.4. 
 
[18F]-PSS223 exhibited similarly high affinity for 
the mGluR5 as [11C]-ABP688, i.e., 3.3 nM com-
pared to 1.7 nM [18], suggesting that the long 
chain in [18F]-PSS223 did not significantly affect 
the binding affinity. The value of Bmax deter-
mined for [18F]-PSS223 (range: 2-6 pmol/mg) 
compared favourably to the Bmax values of [11C]-
ABP688 (231±18 fmol/mg) [18] and [18F]-
FDEGPECO (range: 0.5-4 pmol/mg) [28]. Spe-
cific binding of [18F]-PSS223 to mGluR5-rich 
brain regions in the in vitro autoradiography 
experiments prompted further in vitro and in 
vivo characterization of [18F]-PSS223. 
 
[18F]-PSS223 was stable in buffer and rat 
plasma; however, it was significantly metabo-
lized by the rat liver microsomal enzymes and a 
polar radiometabolite co-eluting with [18F]-
fluoride was observed by UPLC. In the experi-
ments with human liver microsomes, two polar 
radiometabolites were detected albeit in the 
amounts significantly lower than those observed 
with rat microsomal enzymes. Based on the 
control experiments, it was concluded that the 
process was NADPH-dependent, implying the 
involvement of oxidoreductases. One likely 
mechanism involves defluorination preceded by 
the oxygenation of the carbon atom in the α-
position to the fluorine atom [44]. The possible 
mechanism is depicted in Figure 8. A lower de-
gree of metabolic activity of the human com-
pared to that of rat liver microsomes would be 
in agreement with several other studies [45-48].  
Considering the rapid metabolism in vitro and 
the possibility of defluorination in vivo, we per-
formed two dynamic PET scans. PET analysis 
demonstrated rapid wash-out of radioactivity 
from the brain and high accumulation in the 
skull and jaws. Accumulation of [18F]-PSS223 in 
mGluR5-rich brain regions was significantly 
lower than observed for [18F]-FDEGPECO. [18F]-
PSS223 was therefore, not further investigated 
in vivo. The observed radioactivity accumulation 
in bone supports the conclusion that the radi-
ometabolite (or one of the radiometabolites) 
observed with liver microsomes was [18F]-
fluoride. Based on the higher stability of [18F]-
PSS223 in human liver microsomes, less exten-
sive defluorination is expected in humans. 
 
The difference in the in vivo behaviour between 
[18F]-PSS223 and [18F]-FDEGPECO could be at-
tributed to the β-heteroatom effect [49, 50], by 
which primary aliphatic 18F-atoms in a β-position 
to heteroatom (e.g., [18F]-FCH2CH2OR) are found 
to be metabolized at a slower rate. This ration-
ale supports absence of defluorination for [18F]-
FDEGPECO.  
 
Conclusions 
 
In conclusion, the radiosynthesis of [18F]-
PSS223 was accomplished in good radiochemi-
cal yields and high specific radioactivity. The 
new radioligand binds mGluR5 in vitro with low 
nanomolar affinity and shows heterogeneous 
and specific accumulation in vitro in mGluR5-
rich brain regions in autoradiographic studies. 
Although the PET studies with [18F]-PSS223 did 
Figure 8. Likely mechanism of defluorination of [18F]-PSS223 involves cytochrome P450-catalyzed C-oxygenation. The 
aldehyde 9 is oxidized or reduced to the respective carboxylic acid or alcohol while [18F]-fluoride is accumulated in 
bone. 
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not allow a clear-cut visualization of mGluR5 in 
vivo in the rat brain, due to low metabolic stabil-
ity and rapid wash-out, [18F]-PSS223 could po-
tentially find utility in higher animals considering 
that [18F]-PSS223 exhibited higher stability in 
human microsomes.  
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Chemistry 
3-((Tert-butyldimethylsilyl)oxy)propan-1-ol (2): A flame dried flask was charged with 
anhydrous N,N`-dimethylformamide (25 mL) and at ambient temperature under N2 
atmosphere 1,3-propanediol (1.00 mL, 1.05 g, 13.8 mmol, d=1.05) was added and 
the resulting colourless solution was treated with diisopropylethylamine (22.5 mL, 
17.0 g, 131 mmol, d=0.755) in one portion and pale yellow biphasic mixture was 
vigorously stirred and further treated with a solution of tert-butyldimethylchlorosilane 
(2.08 g, 13.8 mmol) in DMF (15 mL) dropwise over 16 min during which time the 
mixture turned cloudy and it was allowed to stir for 6 h. After this time the mixture 
was partitioned between H2O (30 mL) and Et2O (50 mL) and the two layers were well 
shaken and separated. The aqueous phase was extracted with Et2O (2x50 mL). The 
combined organic extracts were washed with 2M aq. HCl (2x50 mL; CAUTION: 
vigorous bubbling), saturated aq. NaHCO3 (1x50 mL), brine (1x50 mL), dried 
(Na2SO4) and concentrated in vacuo to give crude mixture as pale yellow oil (3.78 g). 
The crude product was purified by chromatography on a silica gel column (eluting 
with EtOAc:pentane 3:7) to afford title compound (1.29 g, 6.77 mmol, 49%) as a 
colourless oil: IR (neat) 3358, 2954, 2930, 1741, 1472, 1373, 1251, 1094, 962, 
835, 776 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.84 (t, J = 5.6 Hz, 2H), 3.80 (dd, J = 
10.9, 5.4 Hz, 2H), 2.54 (t, J = 5.3 Hz, 1H), 1.78 (quint, J = 5.6 Hz, 1H), 0.90 (s, 9H), 
0.08 (s, 6H) ppm; 13C NMR (100 MHz, CDCl3) δ 63.0 (2), 62.6 (2), 34.3 (2), 26.1 (3C, 
3), 18.4 (0), −5.3 (2C, 3) ppm; MS (ES+) m/z 191 (M + H)+; HRMS (EI+) m/z 
191.1462 (calcd. for C9H23O2Si: 191.1467).  
3-((Tert-butyldimethylsilyl)oxy)propyl 2-bromoacetate (3): A stirred solution of 3-((tert-
butyldimethylsilyl)oxy)propan-1-ol (818 mg, 4.30 mmol) in anhydrous 
dichloromethane (9 mL) was allowed to cool to 0 °C (the ice bath) and under N2 
atmosphere it was then treated with triethylamine (0.66 mL, 478 mg, 4.73 mmol, 
d=0.726) in one portion followed by 4-dimethylaminopyridine (26.0 mg, 0.22 mmol) 
and finally bromoacetylbromide (0.38 mL, 867 mg, 4.30 mmol, d=2.31) was added 
dropwise over 10 min during which time the mixture turned orange and then yellow 
and cloudy and it was allowed to stir and slowly warm to ambient temperature over 
16 h. After this time the mixture was partitioned between H2O (20 mL) and CH2Cl2 
(10 mL) and the two layers were well shaken and separated. The aqueous phase was 
extracted with CH2Cl2 (2x20 mL). The combined organic extracts were washed with 
H2O (3x20 mL), brine (1x20 mL), dried (Na2SO4) and concentrated in vacuo to give 
crude mixture as brown oily residue (2.49 g). The crude mixture was purified by 
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chromatography on a silica gel column (eluting with gradient EtOAc:pentane 1:18 to 
EtOAc:pentane 1:9) to afford title compound (489 mg, 1.57 mmol, 36%) as a 
colourless oil: IR (neat) 2954, 2931, 2854, 1742, 1473, 1277, 1257, 1103, 1008, 
969, 834 cm–1; 1H NMR (400 MHz, CDCl3) δ 4.28 (t, J = 6.4 Hz, 2H), 3.83 (s, 2H), 
3.71 (t, J = 6.0 Hz, 2H), 1.87 (quint, J = 6.2 Hz, 1H), 0.89 (s, 9H), 0.05 (s, 6H) ppm; 
13C NMR (100 MHz, CDCl3) δ 167.4 (0), 63.5 (2), 59.3 (2), 31.7 (2), 26.1 (3C, 3), 
26.0 (2), 18.5 (0), −5.2 (2C, 3) ppm; HRMS (EI+) m/z 252.9890 ((M – C4H9)+ calcd. 
for C7H14BrO3Si; 252.9896). 
(3-(2-Bromoethoxy)propoxy)(tert-butyl)dimethylsilane (4a): A stirred solution of 3-((tert-
butyldimethylsilyl)oxy)propyl 2-bromoacetate (709 mg, 2.28 mmol) in chloroform (2.2 
mL) under N2 atmosphere was treated with indium(III) bromide (40.4 mg, 0.11 mmol) 
in one portion and triethylsilane (1.46 mL, 1.06 g, 9.12 mmol, d=0.728) was then 
added dropwise (addition time < 1 min) and the resulting heterogeneous mixture was 
allowed to heat at 60 °C (oil bath temperature) over 5 h in a flask equipped with 
condenser. Immediately upon heating mixture turned creamy and yellow. After this 
time the mixture was allowed to cool to ambient temperature and it was then diluted 
with H2O (12 mL) and CH2Cl2 (20 mL) and the two layers were well shaken and 
separated. The aqueous phase was further extracted with CH2Cl2 (2x20 mL). The 
combined organic extracts were washed with brine (1x30 mL), dried (Na2SO4) and 
concentrated in vacuo to give crude mixture as brown oily residue (2.49 g). The crude 
product was purified by chromatography on a silica gel column (eluting with 
EtOAc:pentane 1:18) to afford the title compound (287 mg, 0.97 mmol, 42%) as a 
mixture with (3-(2-bromoethoxy)propoxy)triethylsilane (4b) in a 5:1 NMR ratio, 
respectively: IR (neat) 2954, 2928, 2857, 1471, 1255, 1098, 1006, 836, 776, 745, 
666 cm–1; 1H NMR (400 MHz, CDCl3) δ 3.74 (t, J = 6.3 Hz, 4H, overlapped), 3.71 (t, J 
= 6.2 Hz, 4H, overlapped), 3.59 (t, J = 6.2 Hz, 2H, 4b), 3.58 (t, J = 6.3 Hz, 2H, 4a), 
3.46 (t, J = 6.3 Hz, 4H, overlapped), 1.81 (quint, J = 6.2 Hz, 4H, 4b), 1.79 (quint, J = 
6.2 Hz, 4H, 4a), 0.96 (t, J = 8.0 Hz, 9H, 4b), 0.89 (s, 9H, 4a), 0.60 (q, J = 8.0 Hz, 6H, 
4b), 0.05 (s, 6H, 4a) ppm; MS (EI+) m/z 239 (M – C4H9)+ for 4a and 267 (M – C2H5)+ 
for 4b. This mixture was used for the next step. 
(E)-3-(Pyridin-2-ylethynyl)cyclohex-2-enone O-(2-(3-((tert-
butyldimethylsilyl)oxy)propoxy)ethyl) oxime (6a) and (E)-3-(pyridin-2-
ylethynyl)cyclohex-2-enone O-(2-(3-(triethylsilyl)oxy)propoxy)ethyl) oxime (6b): A flame 
dried flask was charged with (E)-3-(pyridin-2-ylethynyl)cyclohex-2-enone oxime (185 
mg, 0.87 mmol) and anhydrous N,N`-dimethylformamide (10 mL) was added and 
clear pale yellow mixture was treated with sodiumhydride (50 mg of 60% suspension 
in oil, 1.25 mmol) and the resulting bright yellow heterogeneous mixture was stirred 
at ambient temperature under N2 atmosphere for 36 min during which time the 
mixture turned orange. After this time a mixture of (3-(2-bromoethoxy)propoxy)(tert-
butyl)dimethylsilane and (3-(2-bromoethoxy)propoxy)triethylsilane (5:1 ratio, 
respectively, 287 mg, 0.96 mmol) in DMF (7.5 mL) was added dropwise over 8 min 
during which time the mixture turned brown and it was allowed to stir further for 70 
min. After this time the crude mixture was quenched with saturated aq. NaHCO3 (10 
mL) and it was diluted with H2O (40 mL) and Et2O (80 mL) and the two layers were 
well shaken and separated. The aqueous phase was extracted with Et2O (2x80 mL). 
The combined organic extracts were washed with H2O (3x40 mL), brine (1x40 mL), 
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dried (Na2SO4) and concentrated in vacuo to give the crude mixture as a brown oily 
residue (293 mg). The crude product was used for the next step without purification. 
(E)-3-(Pyridin-2-ylethynyl)cyclohex-2-enone O-(2-(3-hydroxypropoxy)ethyl) oxime (7): At 
ambient temperature under N2 atmosphere round bottom flask was charged with the 
crude mixture of (E)-3-(pyridin-2-ylethynyl)cyclohex-2-enone O-(2-(3-((tert-
butyldimethylsilyl)oxy)propoxy)ethyl) oxime and (E)-3-(pyridin-2-ylethynyl)cyclohex-2-
enone O-(2-(3-((triethylsilyl)oxy)propoxy)ethyl) oxime (293 mg, 0.68 mmol) and 
anhydrous tetrahydrofuran (12.3 mL) was added and the resulting clear orange 
mixture was further treated with tetrabutylammoniumfluoride solution in THF (1.4 
mL, 1.36 mmol, c=1M) dropwise over 5 min and the resulting brown mixture was 
allowed to stir at ambient temperature under N2 for 70 min. After this time the 
mixture was partitioned between H2O (30 mL) and EtOAc (40 mL) and the two layers 
were well shaken and separated. The aqueous phase was extracted with EtOAc (2x40 
mL, slow separation of phases). The combined organic extracts were washed with 
H2O (3x30 mL), brine (1x40 mL), dried (Na2SO4) and concentrated in vacuo  to give 
crude mixture as brown oil. The crude product was purified by chromatography on a 
silica gel column (eluting with gradient EtOAc:pentane 9:1 to 100% EtOAc) to give the 
title compound (131 mg, 0.42 mmol) as a pale yellow oil: IR (neat) 3412, 2936, 
2869, 2196, 1581, 1463, 1428, 1358, 1248, 1122, 1059, 978, 958, 861, 779 
cm–1; 1H NMR (400 MHz, CDCl3) δ 8.60 (ddd, J = 4.9, 1.7, 0.9 Hz, 1H), 7.66 (td, J = 
7.8, 1.8 Hz, 1H), 7.45 (dt, J = 7.8, 1.0 Hz, 1H), 7.23 (ddd, J = 7.6, 4.9, 1.2 Hz, 1H), 
6.58 (t, J = 1.6 Hz, 1H), 4.26 (bdm, J = 4.6 Hz, 2H), 3.78 (t, J = 5.5 Hz, 2H), 3.71 
(bdm, J = 4.8 Hz, 2H), 3.72 (bdm, J = 3.5 Hz, 2H), 3.69 (dd, J = 5.7 Hz, 2H), 2.57 (dd, 
J = 6.4 Hz, 2H), 2.40 (td, J = 6.1, 1.6 Hz, 2H), 1.84 (quint, J = 5.6 Hz, 2H), 1.80 
(quint, J = 6.3 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 156.0 (0), 150.2 (1), 143.4 
(0), 136.4 (1), 131.2 (1), 127.6 (0), 127.5 (1), 123.0 (1), 92.0 (0), 90.2 (0), 73.5 (2), 
70.9 (2), 69.8 (2), 62.4 (2), 32.0 (2), 29.6 (2), 22.4 (2), 21.0 (2) ppm; MS (ES+) m/z 
315 (M + H)+; HRMS (ESI) m/z 315.1710 (calcd. for C18H23N2O3: 315.1703). 
(E)-3-(2-(((3-(Pyridin-2-ylethynyl)cyclohex-2-en-1-ylidene)amino)oxy)ethoxy)propyl 
methanesulfonate (8): A stirred solution of (E)-3-(pyridin-2-ylethynyl)cyclohex-2-enone 
O-(2-(3-hydroxypropoxy)ethyl) oxime (131 mg, 0.42 mmol) in anhydrous 
tetrahydrofuran (4.2 mL) was treated with triethylamine (39 µL, 57.0 mg, 0.50 mmol, 
d=1.477) in one portion and methanesulfonylchloride (117 µL, 85.0 mg, 0.84 mmol, 
d=0.726) was then added dropwise (addition time < 1 min) and the resulting pale 
yellow mixture was allowed to stir at ambient temperature under N2 atmosphere for 
22 min during which time white precipitate formed. After this time the mixture was 
partitioned between H2O (16 mL) and EtOAc (20 mL) and the two layers were well 
shaken and separated. The aqueous phase was extracted with EtOAc (2x20 mL). The 
combined organic extracts were washed with H2O (3x16 mL), brine (1x16 mL), dried 
(Na2SO4) and concentrated in vacuo to give crude mixture as pale yellow oil. The 
crude product was purified by chromatography on a silica gel column (eluting with 
gradient EtOAc:pentane 4:1 to 100% EtOAc) to afford the title compound (138 mg, 
0.35 mmol, 85%) as a pale yellow oil: IR (neat) 2933, 2870, 2197, 2097, 1580, 
1462, 1428, 1352, 1173, 1124, 1061, 887, 863, 842, 779, 629 cm–1; 1H NMR 
(400 MHz, CDCl3) δ 8.59 (bdm, J = 4.4 Hz, 1H), 7.65 (td, J = 7.8, 1.8 Hz, 1H), 7.44 
(bdm, J = 7.8 Hz, 1H), 7.22 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H), 6.56 (t, J = 1.5 Hz, 1H), 
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4.34 (t, J = 6.2 Hz, 2H), 4.24 (bdm, J = 4.7 Hz, 2H), 3.70 (bdm, J = 4.8 Hz, 2H), 3.59 
(t, J = 5.9 Hz, 2H), 3.00 (s, 3H), 2.57 (dm, J = 6.5 Hz, 2H), 2.40 (td, J = 6.2, 1.4 Hz, 
2H), 2.01 (quint, J = 6.0 Hz, 2H), 1.80 (quint, J = 6.4 Hz, 2H) ppm; 13C NMR 
(100MHz, CDCl3) δ 155.9 (0), 150.3 (1), 143.4 (0), 136.3 (1), 131.1 (1), 127.6 (0), 
127.4 (1), 123.0 (1), 92.1 (0), 90.0 (0), 73.7 (2), 69.6 (2), 67.5 (2), 66.6 (2), 37.3 
(3), 29.6 (2), 29.5 (2), 22.5 (2), 20.9 (2) ppm; MS (ES+) m/z 393 (M + H)+; HRMS 
(ESI) m/z 393.1489 (calcd. for C19H25N2O5S: 393.1479). 
(E)-3-(Pyridin-2-ylethynyl)cyclohex-2-enone O-(2-(3-fluoropropoxy)ethyl) oxime 
(PSS223): A flame dried round bottom flask was charged with Kryptofix-222® (150 
mg, 0.40 mmol) and potassium fluoride (23.0 mg, 0.40 mmol) and at ambient 
temperature under N2 atmosphere anhydrous acetonitrile (3.2 mL) was added. 
Resulting colourless solution was further treated with a solution of (E)-3-(2-(((3-
(pyridin-2-ylethynyl)cyclohex-2-en-1-ylidene)amino)oxy)ethoxy)propyl 
methanesulfonate (78.0 mg, 0.20 mmol) in anhydrous acetonitrile (3.2 mL) dropwise 
over 2 min during which time the mixture turned pale orange and the mixture was 
allowed to heat at 80 °C (oil bath temperature) for 40 min. The mixture was then 
allowed to cool to ambient temperature and then diluted with H2O (15 mL) and EtOAc 
(25 mL) and the two layers were well shaken and separated. The aqueous phase was 
extracted with EtOAc (2x25 mL, slow separation of phases). The combined organic 
extracts were washed with H2O (3x15 mL), brine (1x15 mL), dried (Na2SO4) and 
concentrated in vacuo to give the title compound (44.1 mg, 0.14 mmol, 70%) as a 
colourless oil: IR (neat): 3050, 2925, 2869, 2205, 1580, 1462, 1358, 1124, 1060, 
978, 864, 778, 741 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.59 (ddd, J = 4.9, 1.8, 0.9 
Hz, 1H), 7.65 (td, J = 7.8, 1.8 Hz, 1H), 7.44 (dt, J = 7.8, 1.0 Hz, 1H), 7.22 (ddd, J = 
7.6, 5.0, 1.2 Hz, 1H), 6.57 (t, J = 1.6 Hz, 1H), 4.55 (dt, J = 47, 5.9 Hz, 2H), 4.25 (dm, 
J = 4.8 Hz, 2H), 3.71 (dm, J = 4.9 Hz, 2H), 3.61 (t, J = 6.2 Hz, 2H), 2.58 (ddm, J = 6.4 
Hz, 2H), 2.40 (td, J = 6.0, 1.5 Hz, 2H), 1.96 (dquint, J = 26, 6.0 Hz, 2H), 1.80 (quint, J 
= 6.4 Hz, 2H) ppm; 13C NMR (100 MHz, CDCl3) δ 156.0 (0), 150.3 (1), 143.6 (0), 
136.3 (1), 131.2 (1), 127.45 (0), 127.42 (1), 123.0 (1), 92.4 (0), 90.1 (0), 81.5 (d, J 
= 141 Hz, 2), 73.8 (2), 69.6 (0), 67.0 (d, J = 5.5 Hz, 2), 31.0 (d, J = 20 Hz, 2), 29.6 
(2), 22.5 (2), 21.0 (2) ppm; 19F NMR (376 MHz, CDCl3) δ –221.8 (ddt, J = 46, 25 Hz) 
ppm; MS (ES+) m/z 317 (M + H)+; HRMS (ESI) m/z 317.1663 (calcd. for 
C18H22FN2O2: 317.1660).  
 
 
 
 
 
 
 
 
 
 
HPLC chromatograph of [18F]-PSS223: Quality control 
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HPLC chromatograph of [18F]-PSS223: Coinjection with cold reference 
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